Candace Mainor

May 10, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-46961-x, published online 27 March 2024The original version of the article file contained some inaccuracies in the main text. To avoid misinterpretation of the findings, the following corrections have now been made in the revised PDF and HTML versions of the article file. Abstract.

Apr 29, 2024 | jamanetwork.com | Jeanne S. Mandelblatt |Candace Mainor |Barry I. Hudson

The Alliance trial led by Chen and colleagues1 and published in this issue of JAMA addresses an important topic in the management of breast cancer: can daily use of 300 mg of aspirin improve invasive disease–free survival among persons with a diagnosis of nonmetastatic, high-risk breast cancer? The answer is a fairly definitive no based on prespecified futility rules in a rigorous phase 3, randomized, placebo-controlled, double-blind trial.

Mar 26, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

AbstractChemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint).